Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects

After experiencing many ups and downs, chimeric antigen receptor (CAR)-T cell therapy has reached a milestone as an anti-cancer method, as evidenced by the increasing number of clinical trials and approved products. Nonetheless, there is a real need to optimize CAR-T cell therapy and overcome its ex...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Mehdi Alidadi, Haniyeh Barzgar, Mohammad Zaman, Olga A. Paevskaya, Yekta Metanat, Elnaz Khodabandehloo, Vahid Moradi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2024-11-01
Serie:	Frontiers in Cell and Developmental Biology
Soggetti:	induced pluripotent stem cell (iPSC) chimeric antigen receptor (CAR) cGMP cancer immunotherapy
Accesso online:	https://www.frontiersin.org/articles/10.3389/fcell.2024.1491282/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!